These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11755578)

  • 21. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures?
    Rosenfeld JA
    West J Med; 2000 Sep; 173(3):186-8. PubMed ID: 10986186
    [No Abstract]   [Full Text] [Related]  

  • 22. Review on raloxifene: profile of a selective estrogen receptor modulator.
    Heringa M
    Int J Clin Pharmacol Ther; 2003 Aug; 41(8):331-45. PubMed ID: 12940590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene vs tamoxifen.
    Goldstein SR
    JAMA; 2007 Jan; 297(3):263-4; author reply 264. PubMed ID: 17227974
    [No Abstract]   [Full Text] [Related]  

  • 24. An update on non-uterine gynaecological effects on raloxifene.
    Goldstein SR
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S65-6. PubMed ID: 12409080
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacological management of severe postmenopausal osteoporosis.
    Gaudio A; Morabito N
    Drugs Aging; 2005; 22(5):405-17. PubMed ID: 15903353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB
    Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Selective estrogen receptor modulators (SERMs)].
    Chaki O
    Nihon Rinsho; 2015 Oct; 73(10):1673-81. PubMed ID: 26529929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of non-alcoholic fatty liver disease (NAFLD) aggravated after treatment with raloxifene].
    Matsumura M; Tashiro K; Miura A; Tajima T; Kinoshita I; Kojima E; Yoshizawa A
    Nihon Shokakibyo Gakkai Zasshi; 2011 Dec; 108(12):2036-41. PubMed ID: 22139492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
    Korsić M
    Reumatizam; 2003; 50(2):55-7. PubMed ID: 15098379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
    Duvernoy CS; Yeo AA; Wong M; Cox DA; Kim HM
    J Womens Health (Larchmt); 2010 Aug; 19(8):1459-65. PubMed ID: 20626269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.
    Mosca L; Grady D; Barrett-Connor E; Collins P; Wenger N; Abramson BL; Paganini-Hill A; Geiger MJ; Dowsett SA; Amewou-Atisso M; Kornitzer M
    Stroke; 2009 Jan; 40(1):147-55. PubMed ID: 18948611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. My doctor wanted me to start taking Evista (raloxifene hydrochloride) for osteoporosis, but I'm worried because the drug is linked to a risk of blood clots. I have mild hypertension that I manage with medications, diet and exercise. Do you think the drug is safe?
    Heart Advis; 2010 May; 13(5):8. PubMed ID: 22816154
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
    Hamaya E; Sowa H
    Menopause; 2014 Jan; 21(1):109-10. PubMed ID: 24281238
    [No Abstract]   [Full Text] [Related]  

  • 35. [Drugs in development for the treatment of osteoporosis:Raloxifene].
    Taga M
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():572-80. PubMed ID: 11979956
    [No Abstract]   [Full Text] [Related]  

  • 36. Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?
    Papadokostakis G; Katonis P; Damilakis J; Hadjipavlou A
    Eur Spine J; 2005 Dec; 14(10):977-81. PubMed ID: 15834592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Images in intensive medicine].
    Córdoba López A; Monterrubio Villar J
    Med Intensiva; 2006; 30(5):247. PubMed ID: 16938203
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis.
    Modugno F; Ness RB; Ewing S; Cauley JA
    Obstet Gynecol; 2003 Feb; 101(2):353-61. PubMed ID: 12576261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
    Goldstein SR; Bhattoa HP; Neven P; Cox DA; Dowsett SA; Alam J; Sipos A; Muram D
    Menopause; 2012 Jan; 19(1):41-7. PubMed ID: 21993078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporosis guidelines.
    Yendt ER
    CMAJ; 2003 Jun; 168(13):1644; author reply 1645-6. PubMed ID: 12821611
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.